Phase solubility studies were performed according to the method reported by Higuchi and Connors, 1965 [10]. The
solubility of the drug was analyzed in distilled water, ethanol, chloroform, acetone, stimulated gastric fluid (pH=1.2)
and phthalate buffer solution (pH 3.4). The excess amounts of drug (100 mg) were transferred in to 10 ml
stopper conical flask. The mixture was diluted by the solvent with stirring up to the mark. The mixture was shaken
in thermostatic shaker bath for 24 hr at 37±5
0
C .The aliquots of 5 ml were withdrawn and filter through a 0.45-µm
Whatman filter paper for determining drug concentration by UV‐spectrophotometer at 334.5 nm. All assays were
performed in triplicate (Table 1). However, stimulated gastric fluid (SGF) and phthalate buffer solution (PBS) were
chosen as a solvent for developing the method of the developed pH sensitive formulation [11] .
Phase solubility studies were performed according to the method reported by Higuchi and Connors, 1965 [10]. The solubility of the drug was analyzed in distilled water, ethanol, chloroform, acetone, stimulated gastric fluid (pH=1.2) and phthalate buffer solution (pH 3.4). The excess amounts of drug (100 mg) were transferred in to 10 ml stopper conical flask. The mixture was diluted by the solvent with stirring up to the mark. The mixture was shaken in thermostatic shaker bath for 24 hr at 37±5 0C .The aliquots of 5 ml were withdrawn and filter through a 0.45-µm Whatman filter paper for determining drug concentration by UV‐spectrophotometer at 334.5 nm. All assays were performed in triplicate (Table 1). However, stimulated gastric fluid (SGF) and phthalate buffer solution (PBS) were chosen as a solvent for developing the method of the developed pH sensitive formulation [11] .
การแปล กรุณารอสักครู่..
